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Abstract
Background Falls cause considerable morbidity and mortality in older people. It is unclear how vitamin D supplemen-
tation affects falls risk, particularly when taken at high doses. We sought to determine whether monthly high-dose vi-
tamin D supplementation reduces risk and incidence of falls.
Methods We used data from the randomized, double-blind, placebo-controlled D-Health Trial conducted in Australia.
Between February 2014 and May 2015, 21 315 participants aged 60–84 years were randomized (1:1) to monthly doses
of either 60 000 IU of colecalciferol or placebo for a maximum of 5 years. People who reported a history of osteomala-
cia, sarcoidosis, hyperparathyroidism, hypercalcaemia or kidney stones or who were taking >500 IU/day supplemen-
tary vitamin D were ineligible. Each year, we collected blood samples from ~450 randomly sampled participants
from each trial arm and measured 25-hydroxyvitamin D [25(OH)D]. Falls, a prespecified tertiary outcome, were
ascertained using annual surveys and, for a subset of participants, 3-month falls diaries. The primary outcome for this
analysis was any fall in the month before completing an annual survey. As part of our process to maintain blinding, we
used random samples of participants (surveys, n = 16 000; diaries, n = 2400), with equal numbers per group. Partic-
ipants with no outcome data were excluded. Following an intention-to-treat approach, we analysed outcomes using lo-
gistic, ordinal and negative binomial regression. Registration: Australian New Zealand Clinical Trials Registry
(ACTRN12613000743763); registered 4 July 2013.
Results Mean treatment duration was 4.3 years (standard deviation [SD] = 1.4 years). Mean serum 25(OH)D concen-
trations during the trial were 114.8 (SD 30.3) nmol/L and 77.5 (SD 25.2) nmol/L in the vitamin D and placebo groups,
respectively. Survey and diary analytic sets included 15 416 and 2200 participants, respectively; approximately half
were randomized to vitamin D (surveys: 50.1%; diaries: 50.4%). Vitamin D had no effect on falling in the past month
(odds ratio [OR] 1.02, 95% confidence interval [CI] 0.95–1.10). There was an interaction with body mass index (BMI)
(P-interaction = 0.001); vitamin D increased risk in participants with BMI < 25 kg/m2 (OR 1.25, 95% CI 1.09–1.43),
but there was no effect in those with BMI ≥ 25 kg/m2 (OR 0.95, 95% CI 0.87–1.04). Analyses of diary data were con-
sistent with these findings. The incidence of hypercalcaemia and kidney stones did not differ between groups.
Conclusions Monthly high-dose vitamin D supplementation did not reduce risk of falling. A possible increased risk of
falling with vitamin D supplementation in people with normal BMI warrants further investigation.
Keywords Randomized controlled trial; Vitamin D; Falls; Bolus dose
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Introduction
Falls cause substantial morbidity and mortality and impose a
considerable burden on health systems. The Global Burden of
Disease Study 2017 ranked falls as the 18th leading cause of
disability-adjusted life years and the second leading cause of
death due to unintentional injury.1 Ageing is associated with
increased falls risk,1 and older people experience a decrease
in daily functional status following an injurious fall.2
Vitamin D deficiency, as measured by serum
25-hydroxyvitamin D [25(OH)D] concentration, is associated
with muscle weakness3,4 and increased falls risk.5 The vitamin
D receptor (VDR) has been identified in skeletal muscle,6 and
myocyte deletion of the VDR in mice results in sarcopenia
and reduced muscle function.7 There is evidence that vitamin
D supplementation acts to improve balance8 and increase
muscle strength.8,9
It is thus plausible that vitamin D supplementation might
protect against falling; however, despite many randomized
controlled trials (RCTs) of vitamin D supplementation, it re-
mains unclear if this is the case. A 2009 meta-analysis esti-
mated that supplementing elderly people with 700–1000 IU
per day of vitamin D reduced risk of falling by 19% (7 RCTs,
n = 1921, relative risk [RR] 0.81, 95% confidence interval
[CI] 0.71–0.92).10 However, a 2018 meta-analysis found sup-
plementation had little effect (37 RCTs, n = 34 144, RR 0.97,
95% CI 0.93–1.02),11 and the large (n = 25 871) Vitamin D
and Omega-3 Trial (VITAL) subsequently reported that sup-
plementation with 2000 IU/day over 5 years did not alter
the risk of having ≥2 falls per year (odds ratio [OR] 0.97,
95% CI 0.90–1.05).12 The recently published Study To Under-
stand Fall Reduction and Vitamin D in You (STURDY) found
that although supplementation with 1000 IU/day did not re-
duce the time to first fall or death over 2 years, it potentially
increased risk of serious falls, when compared with supple-
mentation with 200 IU/day.13
In addition to uncertainty about vitamin D supplementa-
tion’s overall effect on risk of falling, the effect of dosing reg-
imen is also unclear. Three RCTs found intermittent, high
doses of vitamin D supplementation significantly increased
falls risk.14–16 However, a 2015 meta-analysis of RCTs of inter-
mittent, high-dose vitamin D supplementation performed in
older people found no effect (8 RCTs, n = 18 572, RR 1.02,
95% CI 0.96–1.08).17 Likewise, the large (n = 5056) Vitamin
D Assessment (ViDA) Trial found that monthly doses of 100
000 IU vitamin D did not increase risk of falling.18
The D-Health Trial is a population-based RCT of vitamin D
supplementation.19 The objective of the current analysis
was to determine whether long-term supplementation with
monthly high-dose (60 000 IU) vitamin D affects risk of falling
in older people. Our a priori hypothesis was that randomiza-




We have published detailed trial methods.19 Briefly, the D-
Health Trial was a double-blind, randomized, placebo-con-
trolled trial in older Australians. Between February 2014
and May 2015, we randomized 21 315 participants (1:1 ratio)
to monthly doses of either 60 000 IU of colecalciferol (vitamin
D3) or placebo. The primary outcome is all-cause mortality.
Secondary outcomes are total cancer incidence and colorec-
tal cancer incidence. Falls is one of many pre-specified ter-
tiary outcomes.20 The QIMR Berghofer Medical Research
Institute Human Research Ethics Committee approved the
trial. All participants gave written or online consent to
participate.
Participants
Using the Commonwealth electoral roll as the sampling
frame, we invited Australians (excluding people from the
Northern Territory) aged 60–79 years to participate. We
also sought volunteers aged 60–84 years. Participants with
a self-reported history of osteomalacia, sarcoidosis, hyper-
parathyroidism, hypercalcaemia or kidney stones or who
were taking >500 IU/day of supplementary vitamin D were
ineligible.
Randomization
We used computer-generated permuted block randomiza-
tion, stratified by age (60–64, 65–69, 70–74, 75 + years), sex
and state of residence (New South Wales, Queensland, South
Australia, Tasmania, Victoria, Western Australia). Study staff
and investigators did not have access to the allocation
sequence.
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Intervention
Lipa Pharmaceuticals Pty. Ltd. manufactured the active and
placebo gel capsules (identical in appearance). We mailed
blister packs of 12 tablets at baseline and annually thereafter
and instructed participants to take one tablet on the first day
of each month. Reminders were sent via text message, land-
line message and/or email. Participants took study tablets for
a maximum of 5 years.
Baseline characteristics
Participants completed a questionnaire at baseline that
asked about personal, socio-demographic and lifestyle fac-
tors, history of illness and intake of vitamin D (Methods
S1). We did not measure baseline serum 25(OH)D as the
study was not powered for subgroup analyses, and we could
therefore not justify the high cost; rather, we predicted
whether de-seasonalized baseline serum 25(OH)D concentra-
tion was <50 nmol/L using blood samples collected through-
out the trial from a randomly selected subset of participants
randomized to the placebo. The model was constructed
using a training dataset (80% of the samples) and validated
using the remaining 20% of samples (sensitivity, 0.64; speci-
ficity, 0.72; positive predictive value, 0.23; negative predic-




Every 12 months after randomization, we sent annual surveys
to participants, including those who had withdrawn and
agreed to continue surveys. Each survey asked participants
to report whether they had fallen during the previous month.
From annual survey 3 (commencing early 2017) onwards, we
also asked participants to report the number of times they
had fallen in the previous year (none, 1–2, 3–4, 5–9, ≥10
times) and included a definition of a fall (‘fall means uninten-
tionally coming to rest on the ground, floor or other lower
level’).
Falls diaries
Between October 2016 and March 2018 (mean time from
randomization 2.9 years; standard deviation [SD]: 0.5 years;
range: 2.1–3.8 years), we invited 2615 randomly selected par-
ticipants who remained enrolled to complete a falls diary. We
sampled within strata defined by randomization group, age,
sex and state; eligibility was restricted to participants aged
≥65 years at the time of sampling; and we sampled equal pro-
portions of men and women. For 3 months, participants re-
corded whether they had fallen on each day. For each fall
that occurred, we asked participants to indicate what injuries
they suffered.
Primary outcome
The primary outcome for this analysis is the occurrence of
falling in the month prior to completing an annual survey,
using a repeated measures approach to incorporate re-
sponses from all five annual surveys.
Secondary outcomes
Secondary outcomes include (1) falling at least once in the
month prior to individual annual surveys (each year analysed
separately); (2) the number of falls in the year prior to an an-
nual survey (using an upper category of ‘≥3’ due to small
numbers); (3) falling at least once while keeping a falls diary;
and (4) the incidence rate (IR) of falls experienced while
keeping a falls diary.
Compliance monitoring
On each annual survey, we asked participants to report the
number of study tablets taken during the previous year; this
was used to calculate overall compliance (Methods S3). We
also asked about consumption of off-trial supplements con-
taining vitamin D (including multivitamins with vitamin D)
during the previous month. In addition, each year, we mea-
sured serum 25(OH)D concentrations in a random sample of
~450 participants from each trial arm.
Sample size and blinding
Because the primary outcome of the trial (all-cause mortality)
has not yet been analysed, it was important that the current
analysis did not ‘unblind’ D-Health researchers. No analysts
or investigators have access to original D-Health data. An ex-
ternal researcher from QIMR Berghofer’s statistics depart-
ment (not an author of this manuscript) prepared datasets
for these analyses, following the approach previously
described.20 Random samples of 16 000 and 2400 partici-
pants were taken for the analysis of surveys and diaries, re-
spectively, with equal numbers per treatment arm. For the
latter, we sampled from all participants invited to complete
diaries. Study arms were randomly mapped to 0 and 1, and
new person identification codes were generated. After the
main results were finalized, the authors were advised which
of Group 0 and Group 1 was the placebo group. In this way,
blinding was maintained for this analysis and for the trial
overall. In Methods S4, we describe how we will remain
blinded when conducting future analyses.
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Eligibility for current analyses
From the subset of 16 000 participants, we excluded anyone
who did not answer the falls question on ≥1 survey (Table
S1 shows missing data patterns). From the sample of falls di-
ary participants, we excluded anyone who did not return a
diary.
Adverse events
We asked participants to contact us if they experienced any
adverse event. We coded adverse events using the Medical
Dictionary for Regulatory Activities (MedDRA) and classified
the relationship with the intervention as unrelated, unlikely,
possible or probable. We also captured diagnoses of
hypercalcaemia and kidney stones in annual surveys.
Statistical analyses
We performed analyses in SAS Version 9.4 (SAS Institute, Inc.,
Cary, NC) and used R Version 3.6.122 to produce Figures 2 and
S1. Most analyses were pre-specified; Methods S5 describes
all data-driven analyses. Hypothesis tests, when performed,
were two-sided; we used a statistical significance level of
P < 0.05, with no adjustment for multiple testing.
We used chi-squared tests to compare baseline character-
istics of participants who (1) were and were not included in
the analytic populations and (2) completed the trial (i.e. took
tablets for their full planned intervention period) in each ran-
domization group. Associations between selected baseline
characteristics and falls were analysed using regression
models (Methods S6).
Our analysis of the effect of vitamin D supplementation on
falls followed a modified intention-to-treat approach because
we excluded participants who were missing all outcome data
(surveys: 3.7%; diaries: 8.3%) rather than imputing their out-
comes. We used logistic regression to analyse the risk of
experiencing > = 1 fall based on either survey or diary data.
For survey data, we incorporated responses from all surveys
using generalized estimating equations (GEE) with an ex-
changeable correlation matrix to account for participant clus-
tering. To analyse the number of falls in the year prior to an
annual survey, we used ordinal logistic regression. The inci-
dence of falls recorded in diaries and the associated inci-
dence rate ratio (IRR) were estimated using negative
binomial regression. We compared the percentage of falls re-
corded in diaries that resulted in an injury using GEE logistic
regression. All analyses were adjusted for the randomization
stratification variables of age, sex and state of residence.
Analyses of diary data were additionally adjusted for baseline
body mass index (BMI), physical activity and time outdoors,
because these variables showed some imbalance between
randomization groups in the diary analytic set.
We used unadjusted Poisson regression to analyse adverse
events for all 16 000 participants included in the random
sample.
Interactions and subgroup analyses
In pre-specified subgroup analyses,20 we investigated
whether the effect of supplementation was modified by the
following baseline characteristics: age (<70 years;
≥70 years); sex; BMI (<25 kg/m2; ≥25 kg/m2); and predicted
de-seasonalized baseline serum 25(OH)D concentration
(<50 nmol/L; ≥50 nmol/L).
For each factor, we report the P-value for the interaction
term (between randomization group and the factor of inter-
est) based on either the Wald or likelihood ratio statistic.
We also calculated effect estimates within each stratum of
a factor.
To assist with interpretation of results, in exploratory anal-
yses among participants with BMI < 25 kg/m2, we excluded
anyone with BMI < 18.5 kg/m2 (Methods S5).
Results
Trial profile
Detailed baseline characteristics have been published
previously.19 Five people withdrew their consent after ran-
domization, and their data have been deleted. The mean
age of the remaining 21 310 participants was 69.3 (SD 5.5)
years, and 46% (n = 9780) were women. All participants
had finished the intervention by 1 February 2020. The mean
treatment duration was 4.3 (SD 1.4) years (range: 0.0–5.0).
Participants (current analysis)
Analyses of surveys and diaries included 15 416 (96.4%) and
2200 (91.7%) of participants, respectively (Figure 1); approxi-
mately half were randomized to vitamin D (surveys: 50.1%;
diaries: 50.4%). The survey analytic population was very sim-
ilar to the entire D-Health cohort with respect to age (69.2
[SD 5.5] years) and sex (46% [n = 7074] women). By design,
the diary analytic population was older (72.1 [SD 3.6] years)
and had a higher percentage of women (51% [n = 1120]).
The mean BMI was approximately 28 (SD 5) kg/m2 for both
analytic sets. Fully adjusted analyses of diary data included
2093 (95%) participants with complete data for BMI, physical
activity and time outdoors.
Treatment allocation was not associated with being ex-
cluded (randomized to vitamin D [included vs. excluded]:
50% vs. 46% for both surveys [P = 0.08] and diaries
[P = 0.2]). Although some baseline characteristics differed
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between those who were and were not included in analyses
(Table S2), there was very good balance between the study
groups in the analytic populations, with the exception of
small differences in BMI, time outdoors and physical activity
for participants who completed diaries (Table 1).
Falls outcomes over time
The percentage of participants reporting a fall in the month
prior to each annual survey ranged from 3.6% (Year 1) to
7.6% (Year 4). There was a sharp increase from Year 2
Figure 1 Participant flow for analyses of data from annual surveys and falls diaries (CONSORT flow diagram).
Figure 2 Effect of vitamin D supplementation on risk of falling in the past month for all participants and within participant subgroups: analysis of an-
nual survey data using a repeated measures approach to incorporate responses from all five annual surveys. ORs compare vitamin D to placebo and
were estimated using logistic regression with adjustment for randomization stratification variables of age, sex and state of residence at baseline. Each
annual survey asked participants to report whether or not they had experienced a fall during the previous month. The numbers under ‘no. people’
show the number of participants who answered the falls question on at least one annual survey. Generalized estimating equations with an exchange-
able correlation matrix used to account for participant clustering. P-value from Wald test of significance of interaction term. Abbreviation: CI, confi-
dence interval.
Vitamin D supplementation and risk of falling 5
Journal of Cachexia, Sarcopenia and Muscle 2021
DOI: 10.1002/jcsm.12759
Table 1 Baseline characteristics according to randomization group for people included in analyses of data from annual surveys and falls diaries.
n (%)
Annual surveys Falls diaries
Characteristic Vitamin D (n = 7,729) Placebo (n = 7687) Vitamin D (n = 1109) Placebo (n = 1091)
Age (years)
60–64 1934 (25.0) 1924 (25.0) 1 (0.1) 0 (0.0)
65–69 2125 (27.5) 2124 (27.6) 346 (31.2) 354 (32.4)
70–74 2103 (27.2) 2066 (26.9) 473 (42.7) 427 (39.1)
≥75 1567 (20.3) 1573 (20.5) 289 (26.1) 310 (28.4)
Sex
Men 4171 (54.0) 4171 (54.3) 533 (48.1) 547 (50.1)
Women 3558 (46.0) 3516 (45.7) 576 (51.9) 544 (49.9)
Body mass index (kg/m2)
<18.5 56 (0.7) 44 (0.6) 13 (1.2) 9 (0.8)
18.5 to <25 2329 (30.2) 2252 (29.4) 352 (31.9) 297 (27.3)
25 to <30 3208 (41.6) 3320 (43.3) 438 (39.6) 496 (45.6)
≥30 2111 (27.4) 2045 (26.7) 302 (27.3) 286 (26.3)
Missing 25 26 4 3
Highest qualification obtained
None 770 (10.1) 731 (9.6) 125 (11.4) 137 (12.7)
School or intermediate cert. 1311 (17.2) 1257 (16.5) 221 (20.1) 181 (16.8)
Higher school or leaving cert. 1049 (13.7) 1114 (14.7) 138 (12.5) 150 (13.9)
Apprenticeship or cert. 2494 (32.7) 2595 (34.1) 341 (31.0) 352 (32.6)
University degree or higher 2006 (26.3) 1904 (25.0) 275 (25.0) 259 (24.0)
Missing 99 86 9 12
Living alone
No 6150 (80.0) 6144 (80.3) 865 (78.2) 839 (77.1)
Yes 1542 (20.0) 1504 (19.7) 241 (21.8) 249 (22.9)
Missing 37 39 3 3
Alcohol consumption (drinks/week)
<1 1798 (24.1) 1822 (24.6) 267 (25.1) 277 (26.4)
1 to 7 3324 (44.6) 3295 (44.5) 493 (46.3) 468 (44.6)
>7 to 14 1393 (18.7) 1330 (17.9) 189 (17.7) 176 (16.8)
>14 945 (12.7) 965 (13.0) 116 (10.9) 128 (12.2)
Missing 269 275 44 42
Smoking history
Never 4298 (56.0) 4174 (54.8) 634 (57.4) 624 (57.8)
Ex-smoker 3103 (40.4) 3112 (40.8) 438 (39.7) 422 (39.1)
Current 273 (3.6) 336 (4.4) 32 (2.9) 34 (3.1)
Missing 55 65 5 11
Physical activity (METs/week)
Low (<18) 2463 (32.8) 2485 (33.3) 337 (31.4) 376 (35.1)
Moderate (18 to <45) 2502 (33.4) 2470 (33.1) 359 (33.5) 336 (31.4)
High (≥45) 2534 (33.8) 2504 (33.6) 377 (35.1) 358 (33.5)
Missing 230 228 36 21
Time outdoors (hours/week)
Low (<8) 2462 (32.7) 2513 (33.4) 312 (29.0) 372 (34.9)
Moderate (8 to <18) 2480 (32.9) 2503 (33.3) 387 (35.9) 344 (32.3)
High (≥18) 2595 (34.4) 2510 (33.4) 378 (35.1) 350 (32.8)
Missing 192 161 32 25
Chronic pain
No 6006 (78.0) 5970 (77.9) 869 (78.6) 863 (79.4)
Yes 1691 (22.0) 1697 (22.1) 237 (21.4) 224 (20.6)
Missing 32 20 3 4
Self-rated overall health
Excellent or very good 4239 (55.8) 4209 (55.5) 628 (57.8) 603 (55.9)
Good 2740 (36.1) 2741 (36.1) 384 (35.3) 398 (36.9)
Fair or poor 621 (8.2) 638 (8.4) 75 (6.9) 77 (7.1)
Missing 129 99 22 13
Self-rated quality of life
Excellent or very good 5083 (67.2) 5088 (67.6) 739 (68.6) 732 (68.3)
Good 2046 (27.0) 1994 (26.5) 285 (26.5) 296 (27.6)
Fair or poor 435 (5.8) 444 (5.9) 53 (4.9) 44 (4.1)
Missing 165 161 32 19
Self-rated fair or poor memory
No 5655 (73.4) 5579 (72.8) 805 (72.8) 792 (72.9)
Yes 2045 (26.6) 2089 (27.2) 301 (27.2) 295 (27.1)
(Continues)
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(3.9%) to Year 3 (7.2%), corresponding to when the definition
of falling was first included in the survey. The distribution of
number of falls in the year prior to a survey was very stable
across all years in which it was collected (Years 3–5). Approx-
imately 75% of participants reported no falls in the previous
year, and just over 20% reported falling once or twice; the
percentage who reported falling ≥3 times ranged from 3.5%
to 3.7%.
Baseline factors associated with falling
Analyses of survey data showed that older age, worse overall
health, worse quality of life, chronic pain and fair or poor
memory were strongly associated with increased risk of fall-
ing (Tables S3 and S4). In addition, falls were more common
among women, and participants with BMI ≥ 30 kg/m2, and
in those who lived alone or had ever smoked. After adjust-
ment for age, sex, BMI and physical activity, predicted base-
line serum 25(OH)D concentration was not associated with
falling. In analyses of diary data, women and participants
with poorer memory were at greater risk of falling (Tables
S5 and S6).
Effect of vitamin D supplementation on risk and
incidence of falling
Vitamin D had little effect on the risk of falling at least once
(surveys: OR 1.02, 95% CI 0.95–1.10; diaries: fully adjusted
OR [AOR] 1.07, 95% CI 0.84–1.36) (Tables 2 and S7) or on
the risk of falling 1–2 or ≥3 times in the year prior to separate
annual surveys (Table S8). Of those participants who fell
while keeping a diary, most experienced a single fall (vitamin
D, n = 116 [73%]; placebo, n = 123 [80%]); in each group, two
participants experienced the maximum of four falls over
3 months (Table S9). There was little difference in IRs be-
tween the treatment groups (Table 2). Estimates from analy-
ses of diary data adjusted for age, sex and state only (but
restricted to participants with complete data) were not
meaningfully different (Table S10).
Effect of vitamin D supplementation within
participant subgroups
We found significant and consistent interaction effects be-
tween randomization group and BMI (surveys: P = 0.001; di-
aries: P = 0.02). In participants with BMI < 25 kg/m2,
Table 1 (continued)
n (%)
Annual surveys Falls diaries
Characteristic Vitamin D (n = 7,729) Placebo (n = 7687) Vitamin D (n = 1109) Placebo (n = 1091)
Missing 29 19 3 4
Predicted 25(OH)D concentration (nmol/L)
< 50 1,836 (23.8) 1,870 (24.3) 257 (23.2) 276 (25.3)
≥50 5,893 (76.2) 5,817 (75.7) 852 (76.8) 815 (74.7)
cert., certificate; METs, metabolic equivalent tasks.
Table 2 Effect of vitamin D supplementation on risk of falling and incidence of falls
No./total no. (%) or incidence rate
Vitamin D Placebo OR/IRR (95% CI)a
Annual survey data (n = 15 416) n = 7729 n = 7687
Any fall in previous monthb 2174/36 294 (6.0) 2,106/36,007 (5.8) 1.02 (0.95–1.10)
Diary data (N = 2093)c n = 1045 n = 1048
Any fall over 3 months 159/1045 (15.2) 153/1048 (14.6) 1.07 (0.84–1.36)
Number of falls, IR per 1000 PYARd 820 728 1.13 (0.89–1.43)
CI, confidence interval; IRR, incidence rate ratio; OR, odds ratio; PYAR, person-years at risk.
aEstimates compare vitamin D to placebo. ORs estimated using logistic regression; generalized estimating equations with an exchangeable
correlation matrix used to account for participant clustering when analysing annual survey data. IRR estimated using negative binomial
regression. All estimates adjusted for age, sex and state of residence. Analyses of diary data additionally adjusted for body mass index,
physical activity and time outdoors at baseline.
bData analysed using a repeated measures approach to incorporate responses from all five annual surveys. Numerator is the total number
of falls; denominator is the total number of surveys.
cResults presented for people with complete data for all covariates included in the model. Minimally adjusted estimates (adjusted for age,
sex and state) were not meaningfully different (see Table S10).
dGoodness-of-fit chi-squared test (based on the deviance) showed that the model was adequate.
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vitamin D supplementation increased the risk of falling (sur-
veys: OR 1.25, 95% CI 1.09–1.43 [Figure 2]; diaries: AOR
1.72, 95% CI 1.09–2.73 [Table 3]). In contrast, there was no
effect in participants with BMI ≥ 25 kg/m2. Analysis of inci-
dence showed a similar pattern (Table 3). For number of falls
experienced during a year, there was no clear interaction with
BMI except in Year 5 (Table S8).
When we excluded participants with BMI < 18.5 kg/m2
from the ‘normal’ BMI stratum, survey estimates were largely
unaltered (all outcomes; data not shown); however, the AOR
for having ≥1 fall while keeping a diary decreased from 1.72
to 1.60 (95% CI 1.00–2.57). In exploratory analyses, we found
that effect estimates were generally higher in participants
with BMI between 22.5 and <25 kg/m2 compared with
participants with BMI between 18.5 and <22.5 kg/m2
(Table S11).
Based on survey data, vitamin D appeared to be protective
in participants with predicted baseline serum 25(OH)D con-
centration <50 nmol/L and harmful in participants with pre-
dicted concentration ≥50 nmol/L (P-interaction = 0.01)
(Figure 2). However, this was not seen for analyses of diaries
(Table 3).
There was little evidence of effect modification by age or
sex (Tables S12–S14).
Falls resulting in injuries (falls diaries)
In both groups, 9% of participants had ≥1 injurious fall over
3 months (Table S9). The percentage of falls resulting in an
injury was lower in the vitamin D group (52% vs. 58%; AOR
0.75, 95% CI 0.48–1.17). There were eight fractures in total
(four per group), with one participant in the vitamin D
group experiencing two factures from separate falls
(Table S9).
Participant retention and compliance
The mean treatment duration for participants included in
these analyses was higher than for the entire D-Health cohort
(surveys: 4.5 [SD 1.2] years; diaries: 4.9 [SD 0.3] years), with lit-
tle difference between randomization groups. Of the 15 416
participants included in the analysis of survey data, 82%
(n = 12 654) took tablets for their full planned intervention pe-
riod (i.e. completed the trial), with slightly higher study com-
pletion in the vitamin D group (83% vs. 81%) (Table S15).
With the exception of smoking status, baseline characteristics
of participants who completed the trial did not differ between
randomization groups (Table S16). Of the 2762 participants
who did not complete the intervention, 10% (n = 281) ceased
taking tablets due to death. Trial completion was very high
(94%) among participants who completed a falls diary. The
vast majority of participants reported taking ≥80% of their
study tablets (surveys: ~85%; diaries: 98%) (Table S15). Com-
pliance with study tablets decreased over time (Table S17).
For each year of the trial, the percentage of participants
who reported taking no off-trial supplementary vitamin D
was ~80% and ~75% for the vitamin D and placebo groups,
respectively (Table S18). Intake was ≤500 IU/day for most
participants who took off-trial supplementary vitamin D.
There was a clear separation in the distribution of mea-
sured serum 25(OH)D concentrations between the groups
throughout the intervention (Figure S1). The mean serum
25(OH)D concentration of the 2205 blood samples from
1956 participants randomized to vitamin D was 114.8 (SD
30.3) nmol/L; it was 77.5 (SD 25.2) nmol/L for the 2236 blood
Table 3 Diary data: fully adjusted estimates of the effect of vitamin D supplementation on risk of falling and incidence of falls over a 3-month period
within participant subgroups
No. fallers/total no. people (%) IR per 1000 PYAR
Vitamin D Placebo OR (95% CI)a P-intb Vitamin D Placebo IRR (95% CI)a P-intb
Age (years) 0.13 0.32
<70 45/329 (13.7) 56/341 (16.4) 0.81 (0.52–1.25) 674 733 0.92 (0.61–1.38)
≥70 114/716 (15.9) 97/707 (13.7) 1.24 (0.92–1.67) 839 677 1.24 (0.93–1.65)
Sex 0.79 0.69
Men 70/509 (13.8) 69/533 (12.9) 1.11 (0.77–1.59) 760 648 1.17 (0.82–1.68)
Women 89/536 (16.6) 84/515 (16.3) 1.05 (0.76–1.46) 886 816 1.09 (0.80–1.48)
Body mass index (kg/m2) 0.02 0.17
<25 60/345 (17.4) 34/298 (11.4) 1.72 (1.09–2.73) 888 607 1.46 (0.94–2.28)
≥25 99/700 (14.1) 119/750 (15.9) 0.88 (0.66–1.18) 758 755 1.00 (0.76–1.32)
Predicted 25(OH)D concentration (nmol/L) 0.72 0.59
<50 45/235 (19.1) 44/256 (17.2) 1.12 (0.70–1.80) 895 719 1.25 (0.82–1.90)
≥50 114/810 (14.1) 109/792 (13.8) 1.04 (0.78–1.39) 777 715 1.09 (0.82–1.44)
CI, confidence interval; IR(R), incidence rate (ratio); OR, odds ratio; P-int, P-value for interaction; PYAR, person-years at risk.
aORs and IRRs (comparing vitamin D to placebo) were estimated using logistic and negative binomial regression, respectively. All estimates
adjusted for baseline values of age, sex, state of residence, body mass index, physical activity and time outdoors; analyses were restricted
to people who had complete data for all these covariates (n = 2093). Minimally adjusted estimates (age, sex, and state) were not mean-
ingfully different (see Table S10).
bP-values from Wald test or likelihood ratio test of significance of interaction term.
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samples taken from 1987 participants randomized to pla-
cebo. In the vitamin D group, the mean decreased with in-
creasing BMI category (<25 kg/m2: 121.0 [SD 32.6] nmol/L;
25–<30 kg/m2: 114.3 [SD 29.6] nmol/L; >30 kg/m2: 106.9
[SD 26.3] nmol/L). Only 13% of samples from the placebo
group had serum 25(OH)D concentration < 50 nmol/L.
Adverse events
Participants randomized to vitamin D had a lower incidence
of adverse events of any type and any severity (IR per 1000
person-years at risk [PYAR] 59 vs. 64, IRR 0.92; 95% CI
0.86–0.97). Table S19 shows adverse events according to
MedDRA System Organ Classes. IRs (per 1000 PYAR; vitamin
D vs. placebo) did not differ materially between groups for
adverse events (of any type) classified as possibly or probably
related to the intervention (IRR 0.91, 95% CI 0.80–1.04),
hypercalcaemia (IR 1.5 vs. 1.6, IRR 0.91, 95% CI 0.62–1.33)
or kidney stones (IR 3.3 vs. 3.1, IRR 1.08, 95% CI 0.83–1.41).
The total number of falls reported to study staff on an ad
hoc basis was very similar between groups (vitamin D,
n = 86; placebo, n = 84) (Table S20). Although the percentage
of falls resulting in hospitalization was higher in participants
randomized to vitamin D (45.3%) compared with placebo
(40.5%), the IRs for falls resulting hospitalization were similar
(IR 1.1 vs. 1.0) (Table S20).
Discussion
We found that, overall, long-term monthly supplementation
with 60 000 IU of vitamin D3 had no effect on risk of falling
in older Australians. However, in participants with baseline
BMI < 25 kg/m2, the risk of falling was higher among those
randomized to vitamin D.
The percentage of participants who reported falling is con-
sistent with expectations. When a definition of falling was in-
cluded in the surveys, ~7.5% of D-Health participants
reported falling in the previous month, and 25% reported
≥1 fall over the previous 12 months. There are limited Austra-
lian data with which to compare the risk of falling, as only
falls resulting in hospitalization are routinely reported.23
However, our findings are closely aligned with those of the
ViDA Trial participants (mean age, 66 years), among whom
6% reported falling in the 4 weeks prior to baseline
assessment.18 Our annual figures are also broadly consistent
with the finding that 29% of people in the United States aged
≥65 years fell at least once during 2014.24 As expected,25,26
we found that factors associated with poorer health and
physical decline were also strongly associated with increased
risk of falling.
Our finding of no overall effect is consistent with recent
meta-analyses.11,17 The subsequently published VITAL Trial
(the largest RCT of high-dose vitamin D supplementation to
date) that used the same daily equivalent dose as D-Health
also found no effect on the risk of having two or more falls
per year.12
Concerns have been raised about the safety of intermittent,
high-dose vitamin D supplementation,27 with increased falls
risk seen in three previous RCTs that used bolus doses of vita-
min D3.
14–16 All were performed in populations selected to be
at increased risk of falling (elderly women at high risk of
fracture,14 people with a history of falling15 and long-term care
residents16), two had very small samples (n < 70 per group),
and only one included a placebo group.14 The largest of these
(n = 2256) found that annual doses of 500 000 IU over 3–
5 years increased incidence of falls (IRR 1.15, 95% CI, 1.02–
1.30); baseline BMI was not reported.14 The other two supple-
mented participants with monthly doses over 1 year and re-
ported increased risk15 and incidence16 in the high-dose
group (≥1 fall, 60 000 IU vs. 24 000 IU: 67% vs. 48%; 100
000 IU vs. standard dose [equivalent to 400–1000 IU/day]:
IRR 2.33, 95% CI 1.49–3.63). Differences in age, sex and inter-
vention mean that these results cannot be readily compared
with those from the D-Health Trial.
Despite evidence of increased risk in these studies, the
2018 meta-analysis found no effect of bolus dosing on risk
of falling.11 The New Zealand ViDA Trial was the largest RCT
of intermittent, high-dose vitamin D3 supplementation in-
cluded. It had a similar study design to the D-Health Trial
and found that monthly doses of 100 000 IU over 2.5–
4.2 years had no effect on falls (hazard ratio [HR] 0.99, 95%
CI 0.92–1.07).18
The 2018 meta-analysis did not find any interaction be-
tween vitamin D supplementation and BMI, although the
BMI cut-point used was higher (30 kg/m2) than in our analysis
and dosing regimen was not considered.11 In contrast to our
results, VITAL found a suggestion that vitamin D supplemen-
tation reduced falls in participants with BMI < 25 kg/m2
(≥2 falls per year: OR 0.88, 95% CI 0.76–1.02), although the
interaction with BMI was not significant (p = 0.07). The ViDA
study did not test for interaction with BMI.
To the best of our knowledge, our study is the first to sug-
gest that intermittent supplementation with high-dose vita-
min D may increase the risk of falling in people with
BMI < 25 kg/m2 while having little effect in people with
BMI ≥ 25 kg/m2. Whereas subgroup analyses should be
viewed with caution, the results were consistent across anal-
yses of surveys and diaries, suggesting that this may be a true
effect. Exploratory analyses demonstrated that results were
not driven by outcomes among ‘underweight’ participants.
Explanations for a possible deleterious effect of high-dose vi-
tamin D are currently speculative.28 Supraphysiological doses
of vitamin D have the potential to saturate the vitamin D
binding protein, leading to displacement of 1,25(OH)D and
25(OH)D into the circulation in the days after
supplementation.29 It is plausible that this effect would be
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greater in people with lower body fat, and we showed that
those with normal BMI achieved the highest levels of serum
25(OH)D. However, it is not clear why this would increase risk
of falling.
In analyses of survey data, there was a suggestion that
supplementation might be protective in participants with
lower predicted baseline serum 25(OH)D concentrations
and harmful for those with higher predicted concentra-
tions. The inverse association between BMI and serum 25
(OH)D concentrations makes it difficult to disentangle the
influence of these factors. Because this effect was not seen
in analyses of diary data, the model we developed to pre-
dict baseline serum 25(OH)D concentrations was only mod-
erately reliable,21 and the predicted values have random
error that has not been accounted for here, these results
should be interpreted cautiously. The lack of measured
baseline 25(OH)D concentrations is a weakness of this
study.
An exploratory analysis of adverse events reported on an
ad hoc basis, performed after unblinding, suggested that,
compared with the placebo group, a greater percentage of
falls experienced by participants randomized to vitamin D
resulted in hospitalization. However there was no meaning-
ful difference in the IRs for falls resulting in hospitalization,
and analyses of diary data (collected systematically) showed
that participants in both groups were equally likely to expe-
rience at least one injurious fall over 3 months. Neverthe-
less, the result is consistent with the findings of the small
(n = 647) STURDY trial performed in older adults with ele-
vated risk of falling.13 In a comparison of daily supplementa-
tion with 1000 IU vs. 200 IU, the higher dose had no benefit
overall (HR 0.94, 95% CI 0.76–1.15) and actually appeared
to increase the risk of serious falls (HR 1.87, 95% CI 1.03–
3.41) and falls requiring hospitalization (HR 2.48, 95% CI
1.13–5.46).13
Although using falls diaries allowed us to collect accurate
information, estimates based on these data might be biased.
Despite adjusting analyses of diaries for characteristics that
showed some imbalance between trial arms, residual
confounding remains a possibility.
Vitamin D testing is widespread in Australia,30 and D-Health
participants who suspected that they had been randomized to
placebo may have decided to withdraw or start taking off-trial
vitamin D supplementation in doses higher than permitted by
the study protocol. We only collected blood from participants
who remained in the trial at the time the blood collection was
due, and ~20% of participants invited to give blood declined
(mostly because of lack of easy access to a pathology collection
centre). Nevertheless, the clear and sustained separation in
the distribution of serum 25(OH)D concentrations between
the trial arms suggests that contamination of the placebo
group was not a serious problem.
The D-Health Trial has several strengths. Excellent reten-
tion, compliance and survey completion rates, combined with
the long duration of the intervention, increase our confi-
dence that our main null finding of no effect is robust. All re-
searchers remained blinded to treatment allocation until all
analyses of falls outcomes were completed, and we have
taken careful steps to ensure that blinding was maintained
for the trial overall.
Our results are likely to be generalizable to the general
older Australian population, despite the D-Health cohort be-
ing, on average, somewhat healthier19; the mean 25(OH)D
concentration in the placebo group in the D-Health Trial
was reasonably similar to that in the Australian Health Survey
(78 vs. 69 nmol/L).31 However, we cannot extrapolate from
our results to populations with a high prevalence of vitamin
D deficiency. Because it is ethically questionable to perform
a placebo-controlled trial of vitamin D supplementation in
people who are vitamin D deficient, we recommend
high-quality observational studies be undertaken; this will
help elucidate the relationship between serum 25(OH)D
concentrations and falls risk.
In conclusion, our results do not support the use of
monthly high-dose vitamin D supplementation for falls pre-
vention. The evidence of increased risk in people with
BMI < 25 kg/m2 warrants further investigation, ideally
through reanalysis of existing trials. In the meantime, caution
should be used in prescribing high-dose vitamin D to older
adults in the normal BMI range and who are vitamin D
replete.
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